Last reviewed · How we verify
SHR-A1811 Injection ； Pertuzumab Injection
Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, inhibiting tumor cell growth signaling.
Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, inhibiting tumor cell growth signaling. Used for HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy), HER2-positive early breast cancer (neoadjuvant and adjuvant settings).
At a glance
| Generic name | SHR-A1811 Injection ； Pertuzumab Injection |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | HER2 inhibitor monoclonal antibody |
| Target | HER2 (human epidermal growth factor receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pertuzumab targets the extracellular domain II of HER2, preventing ligand-induced heterodimerization of HER2 with HER3 and other HER family members. This dual mechanism—direct HER2 blockade combined with prevention of HER2-HER3 signaling—leads to reduced phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathway activation, resulting in cell cycle arrest and apoptosis in HER2-overexpressing tumors.
Approved indications
- HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)
- HER2-positive early breast cancer (neoadjuvant and adjuvant settings)
Common side effects
- Diarrhea
- Nausea
- Fatigue
- Vomiting
- Rash
- Left ventricular dysfunction
- Neutropenia
Key clinical trials
- A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer (PHASE3)
- A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer (PHASE3)
- A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: